Skip to main content
Erschienen in: International Journal of Hematology 2/2016

18.03.2016 | Progress in Hematology

Clinical significance of acquired somatic mutations in aplastic anaemia

verfasst von: J. C. W. Marsh, G. J. Mufti

Erschienen in: International Journal of Hematology | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Aplastic anaemia (AA) is frequently associated with other disorders of clonal haemopoiesis such as paroxysmal nocturnal haemoglobinuria (PNH), myelodysplastic syndrome (MDS) and T-large granular lymphocytosis. Certain clones may escape the immune attack within the bone marrow environment and proliferate and attain a survival advantage over normal haemopoietic stem cells, such as trisomy 8, loss of heterozygosity of short arm of chromosome 6 and del13q clones. Recently acquired somatic mutations (SM), excluding PNH clones, have been reported in around 20–25 % of patients with AA, which predispose to a higher risk of later malignant transformation to MDS/acute myeloid leukaemia. Furthermore, certain SM, such as ASXL1 and DNMT3A are associated with poor survival following immunosuppressive therapy, whereas PIGA, BCOR/BCORL1 predict for good response and survival. Further detailed and serial analysis of the immune signature in AA is needed to understand the pathogenetic basis for the presence of clones with SM in a significant proportion of patients.
Literatur
1.
2.
Zurück zum Zitat Young NS, Bacigalupo A, Marsh JCW. Aplastic anemia: pathophysiology and treatment. Biol Blood Marrow Transplant. 2010;16(1):S119–25.CrossRefPubMed Young NS, Bacigalupo A, Marsh JCW. Aplastic anemia: pathophysiology and treatment. Biol Blood Marrow Transplant. 2010;16(1):S119–25.CrossRefPubMed
3.
Zurück zum Zitat Kordasti S, et al. Functional characterization of CD4+ T-cells in Aplastic Anemia. Blood. 2012;119:2033–43.CrossRefPubMed Kordasti S, et al. Functional characterization of CD4+ T-cells in Aplastic Anemia. Blood. 2012;119:2033–43.CrossRefPubMed
4.
Zurück zum Zitat Bennett JM, Orazi A. Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recommendations for a standardized approach. Haematologica. 2009;94:264–8.CrossRefPubMedPubMedCentral Bennett JM, Orazi A. Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recommendations for a standardized approach. Haematologica. 2009;94:264–8.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Gupta V, et al. Clinical relevance of cytogenetics abnormalities in adult patients with acquired aplastic anaemia. Br J Haematol. 2006;134:95–9.CrossRefPubMed Gupta V, et al. Clinical relevance of cytogenetics abnormalities in adult patients with acquired aplastic anaemia. Br J Haematol. 2006;134:95–9.CrossRefPubMed
6.
Zurück zum Zitat Jerez A, et al. STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. Blood. 2013;122:2453–9.CrossRefPubMedPubMedCentral Jerez A, et al. STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. Blood. 2013;122:2453–9.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Haferlach T, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28:241–7.CrossRefPubMed Haferlach T, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28:241–7.CrossRefPubMed
8.
Zurück zum Zitat Papaemmanuil E, et al. Chronic Myeloid Disorders Working Group of the International Cancer Genome; Consortium. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122:3616–27.CrossRefPubMedPubMedCentral Papaemmanuil E, et al. Chronic Myeloid Disorders Working Group of the International Cancer Genome; Consortium. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122:3616–27.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Maciejewsk JP, et al. Impaired hematopoiesis in paroxysmal nocturnal haemoglobinuria/aplasticanemia is not associated with a selective proliferative defect in the glycosylphosphatidyl-inositol-anchored protein-deficient clone. Blood. 1997;89:1173–81. Maciejewsk JP, et al. Impaired hematopoiesis in paroxysmal nocturnal haemoglobinuria/aplasticanemia is not associated with a selective proliferative defect in the glycosylphosphatidyl-inositol-anchored protein-deficient clone. Blood. 1997;89:1173–81.
10.
Zurück zum Zitat Murakami Y, et al. Inefficient response of T lymphocytes to glycosylphosphatidyl-inositol-anchor-negative cells: implications for paroxysmal nocturnal hemoglobinuria. Blood. 2002;100:4116–22.CrossRefPubMed Murakami Y, et al. Inefficient response of T lymphocytes to glycosylphosphatidyl-inositol-anchor-negative cells: implications for paroxysmal nocturnal hemoglobinuria. Blood. 2002;100:4116–22.CrossRefPubMed
11.
Zurück zum Zitat Risitano AM, et al. Large granular lymphocyte (LGL)- like clonal expansions in paroxysmal nocturnal hemoglobinuria (PNH) patients. Leukemia. 2005;19:217–22.CrossRefPubMed Risitano AM, et al. Large granular lymphocyte (LGL)- like clonal expansions in paroxysmal nocturnal hemoglobinuria (PNH) patients. Leukemia. 2005;19:217–22.CrossRefPubMed
12.
Zurück zum Zitat Va Bijnen ST, et al. T cells expressing the activating NK-cell receptors KIR2DS4, NKG2C and NKG2D are elevated in paroxysmal nocturnal hemoglobinuria and cytotoxic toward hematopoietic progenitor cell lines. Exp Hematol. 2011;39:751–62 (e1–3).CrossRef Va Bijnen ST, et al. T cells expressing the activating NK-cell receptors KIR2DS4, NKG2C and NKG2D are elevated in paroxysmal nocturnal hemoglobinuria and cytotoxic toward hematopoietic progenitor cell lines. Exp Hematol. 2011;39:751–62 (e1–3).CrossRef
13.
Zurück zum Zitat Gargiulo L, et al. Glycosylphosphatidylinositol-specific, CD1d-restricted T cells in paroxysmal nocturnal hemoglobinuria. Blood. 2013;121:2753–61.CrossRefPubMed Gargiulo L, et al. Glycosylphosphatidylinositol-specific, CD1d-restricted T cells in paroxysmal nocturnal hemoglobinuria. Blood. 2013;121:2753–61.CrossRefPubMed
14.
Zurück zum Zitat Sloand EM, Pfannes L, Chen G, et al. CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins. Blood. 2007;109:2399–405.CrossRefPubMedPubMedCentral Sloand EM, Pfannes L, Chen G, et al. CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins. Blood. 2007;109:2399–405.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Hosokawa K, et al. Increased glycosylphosphatidylinositol-anchored protein-deficient granulocytes define a benign subset of bone marrow failures in patients with trisomy 8. Eur J Hematol. 2015;95:230–8.CrossRef Hosokawa K, et al. Increased glycosylphosphatidylinositol-anchored protein-deficient granulocytes define a benign subset of bone marrow failures in patients with trisomy 8. Eur J Hematol. 2015;95:230–8.CrossRef
16.
Zurück zum Zitat Katagiri T, Sato-Otsubo A, Kashiwase K, et al. Frequent loss of HLA alleles associated with copy number-neutral 6pLOH in acquired aplastic anemia. Blood. 2011;118:6601–9.CrossRefPubMed Katagiri T, Sato-Otsubo A, Kashiwase K, et al. Frequent loss of HLA alleles associated with copy number-neutral 6pLOH in acquired aplastic anemia. Blood. 2011;118:6601–9.CrossRefPubMed
17.
Zurück zum Zitat Hosokawa K, Katagiri T, Sugimori N, et al. Favorable outcome of patients who have 13q deletion: a suggestion for revision of the WHO ‘MDS-U’ designation. Haematologica. 2012;97:1845–9.CrossRefPubMedPubMedCentral Hosokawa K, Katagiri T, Sugimori N, et al. Favorable outcome of patients who have 13q deletion: a suggestion for revision of the WHO ‘MDS-U’ designation. Haematologica. 2012;97:1845–9.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488–98.CrossRefPubMedPubMedCentral Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488–98.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Genovese G, Kahler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371:2477–87.CrossRefPubMedPubMedCentral Genovese G, Kahler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371:2477–87.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Schlush LI, et al. Aging, clonal hematopoiesis and pre-leukemia: not just bad luck? Int J Hematol. 2015;102:513–22.CrossRef Schlush LI, et al. Aging, clonal hematopoiesis and pre-leukemia: not just bad luck? Int J Hematol. 2015;102:513–22.CrossRef
22.
23.
25.
Zurück zum Zitat Babushok DV, et al. Emergence of clonal hematopoiesis in the majority of patients with acquired aplastic anemia. Cancer Genet. 2015;208:115–28.CrossRefPubMedPubMedCentral Babushok DV, et al. Emergence of clonal hematopoiesis in the majority of patients with acquired aplastic anemia. Cancer Genet. 2015;208:115–28.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Kulasekararaj AG, et al. Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome. Blood. 2014;124:2698–704.CrossRefPubMedPubMedCentral Kulasekararaj AG, et al. Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome. Blood. 2014;124:2698–704.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Yoshizato T, et al. Somatic mutations and clonal hematopoiesis in aplastic anaemia. N Eng J Med. 2015;373:35–47.CrossRef Yoshizato T, et al. Somatic mutations and clonal hematopoiesis in aplastic anaemia. N Eng J Med. 2015;373:35–47.CrossRef
29.
Zurück zum Zitat Kwok B, et al. MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood. 2015;126:2355–61.CrossRefPubMedPubMedCentral Kwok B, et al. MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood. 2015;126:2355–61.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Mufti GJ, Kulasekararaj AG, Marsh JC. Somatic mutations and clonal hematopoiesis in Aplastic Anemia. N Engl J Med. 2015;373:1674–5.PubMed Mufti GJ, Kulasekararaj AG, Marsh JC. Somatic mutations and clonal hematopoiesis in Aplastic Anemia. N Engl J Med. 2015;373:1674–5.PubMed
31.
Zurück zum Zitat Risitano AM, et al. The RACE study: a SAAWP prospective randomized multicenter study comparing horse antithymocyte globulin (hATG) + cyclosporine A (CsA) with or without eltrombopag as front-line therapy for severe aplastic anaemia patients (WP007). Bone Marrow Transplant. 2015;50(S1):pS99. Risitano AM, et al. The RACE study: a SAAWP prospective randomized multicenter study comparing horse antithymocyte globulin (hATG) + cyclosporine A (CsA) with or without eltrombopag as front-line therapy for severe aplastic anaemia patients (WP007). Bone Marrow Transplant. 2015;50(S1):pS99.
33.
Zurück zum Zitat Desmond, et al. Eltrombopag restores tri-lineage hematopoiesis in refractory severe aplastic anemia which can be sustained on discontinuation of drug. Blood. 2014;123:1818–25.CrossRefPubMedPubMedCentral Desmond, et al. Eltrombopag restores tri-lineage hematopoiesis in refractory severe aplastic anemia which can be sustained on discontinuation of drug. Blood. 2014;123:1818–25.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Marsh JC, Mufti GJ. Eltrombopag: a stem cell cookie? Blood. 2014;20(123):1774–5.CrossRef Marsh JC, Mufti GJ. Eltrombopag: a stem cell cookie? Blood. 2014;20(123):1774–5.CrossRef
35.
Zurück zum Zitat Scheinberg P, et al. Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia. JAMA. 2010;304:1358–64.CrossRefPubMedPubMedCentral Scheinberg P, et al. Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia. JAMA. 2010;304:1358–64.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Scheinberg P, et al. Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br J Haematol. 2009;144:206–16.CrossRefPubMed Scheinberg P, et al. Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br J Haematol. 2009;144:206–16.CrossRefPubMed
37.
Zurück zum Zitat Bacigalupo A, et al, for the Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation (WPSAA-EBMT). Current outcome of HLA identical sibling vs. unrelated donor transplants in severe aplastic anemia: an EBMT analysis. Haematologica. 2015; 100: 696–702. Bacigalupo A, et al, for the Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation (WPSAA-EBMT). Current outcome of HLA identical sibling vs. unrelated donor transplants in severe aplastic anemia: an EBMT analysis. Haematologica. 2015; 100: 696–702.
38.
Zurück zum Zitat Marsh JC, et al. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft versus host disease after allogeneic stem cell transplantation for acquired aplastic anemia. Blood. 2011;118:2351–7.CrossRefPubMed Marsh JC, et al. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft versus host disease after allogeneic stem cell transplantation for acquired aplastic anemia. Blood. 2011;118:2351–7.CrossRefPubMed
39.
Zurück zum Zitat Grimaldi, et al. King’s College Hospital FCC conditioning for severe aplastic anemia induces tolerance with mixed T-cell chimerism and extremely low incidence of Gvhd. Blood (Annual Scientific Meeting). 2014;124:1594. Grimaldi, et al. King’s College Hospital FCC conditioning for severe aplastic anemia induces tolerance with mixed T-cell chimerism and extremely low incidence of Gvhd. Blood (Annual Scientific Meeting). 2014;124:1594.
40.
Zurück zum Zitat Samarasinghe S, et al. Impact of different in vivo T cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anaemia: a study on behalf of the EBMT SAA Working Party. Blood (Annual Scientific Meeting). 2015;126(23):1210. Samarasinghe S, et al. Impact of different in vivo T cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anaemia: a study on behalf of the EBMT SAA Working Party. Blood (Annual Scientific Meeting). 2015;126(23):1210.
41.
Zurück zum Zitat Socié G, et al. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. N Engl J Med. 1993;329:1152–7.CrossRefPubMed Socié G, et al. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. N Engl J Med. 1993;329:1152–7.CrossRefPubMed
42.
Zurück zum Zitat Kojima S, et al. Japan Childhood Aplastic Anemia Study Group. Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. Blood. 2002;100(3):786–90.CrossRefPubMed Kojima S, et al. Japan Childhood Aplastic Anemia Study Group. Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. Blood. 2002;100(3):786–90.CrossRefPubMed
43.
Zurück zum Zitat Kordasti S, et al. High resolution mass cytometry (CyTOF) in aplastic anaemia (AA) can identify an aberrant Treg subset with pro-inflammatory properties, predicting poor response to immunosuppressive therapy. Blood. 2014;124:1600 (Annual Scientific Meeting of American Society of Hematology). Kordasti S, et al. High resolution mass cytometry (CyTOF) in aplastic anaemia (AA) can identify an aberrant Treg subset with pro-inflammatory properties, predicting poor response to immunosuppressive therapy. Blood. 2014;124:1600 (Annual Scientific Meeting of American Society of Hematology).
Metadaten
Titel
Clinical significance of acquired somatic mutations in aplastic anaemia
verfasst von
J. C. W. Marsh
G. J. Mufti
Publikationsdatum
18.03.2016
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 2/2016
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-016-1972-8

Weitere Artikel der Ausgabe 2/2016

International Journal of Hematology 2/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.